|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
PHARMA & BIOTECH LICENSING & DEAL-MAKING SUMMIT | ||||||||||||||||
May 14, 2001 | ||||||||||||||||
Strategic Research Institute, The Rittenhouse Hotel, Philadelphia, PA June 4-5, 2001 -Deals -Structure -Valuation -Compensation -Hot Enabling Technologies -Key Therapeutic Classes Deals! -The Human Genome Sciences - Cambridge Antibody Technologies Collaboration -The Genzyme Molecular Oncology - Pudue Pharma Alliance in Immunotherapy -The CuraGen and Bayer AG Alliance - Landmark Drug Discovery, Development and Pharmacogenomic Partnership -Taarget Family Deal Making: The Vertex - Novartis Collaboration -Spreading Risk Across Early-Stage Collaborations Through Structured Financing Arrangements - Elan Corporation -The story of a Development and Commercialization Agreement: The Bristol-Myers Squibb - Otsuka Partnership |
||||||||||||||||
Organized by: | Strategic Research Institute | |||||||||||||||
Invited Speakers: | THE FOLLOWING ARE CONFIRMED TO SPEAK: CHEIL JEDANG PHARMACEUTICALS, METHA PARTNERS LLC, HUMAN GENOME SCIENCES, INC., ELAN CORPORATION, HOFFMAN-LA ROCHE, ALKERMES, INC., LORUSSO & LOUD, GENZYME MOLECULAR ONCOLOGY, ELI LILLY & COMPANY, LEGG MASON WOOD WALKER, CURAGEN CORPORATION, VERTEX PHARMACEUTICALS, BRISTOL-MYERS SQUIBB, LION BIOSCIENCES, INC., NIH OFFICE OF TECHNOLOGY TRANSFER, BROOKHAVEN NATIONAL LABORATORY. |
|||||||||||||||
Deadline for Abstracts: | all have been submitted | |||||||||||||||
Registration: | To Register Call 1-888-666-8514 | |||||||||||||||
E-mail: | science@srinstitute.com | |||||||||||||||
Posted by: | edrilon | |||||||||||||||
Host: | 12.3.58.10 | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |